BioTime, Inc. (NYSEAMERICAN:BTX) was the target of a significant growth in short interest in October. As of October 31st, there was short interest totalling 14,481,443 shares, a growth of 2.0% from the October 15th total of 14,198,940 shares. Based on an average daily volume of 341,212 shares, the days-to-cover ratio is currently 42.4 days. Approximately 11.5% of the company’s stock are short sold.

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. grew its stake in shares of BioTime by 3.1% during the third quarter. BlackRock Inc. now owns 6,102,467 shares of the biotechnology company’s stock worth $14,340,000 after acquiring an additional 185,826 shares during the last quarter. Destination Wealth Management purchased a new stake in BioTime in the third quarter valued at approximately $1,237,000. Northern Trust Corp boosted its position in BioTime by 5.2% in the second quarter. Northern Trust Corp now owns 1,016,226 shares of the biotechnology company’s stock valued at $2,094,000 after buying an additional 49,778 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in BioTime by 4.7% in the second quarter. Bank of New York Mellon Corp now owns 744,554 shares of the biotechnology company’s stock valued at $1,534,000 after buying an additional 33,350 shares during the last quarter.

Separately, Zacks Investment Research upgraded shares of BioTime from a “hold” rating to a “buy” rating and set a $2.50 target price for the company in a report on Wednesday, August 8th.

Shares of BTX stock opened at $1.92 on Friday. BioTime has a fifty-two week low of $1.80 and a fifty-two week high of $3.16.

BioTime (NYSEAMERICAN:BTX) last issued its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by ($0.01). The firm had revenue of $0.98 million during the quarter, compared to analyst estimates of $0.75 million.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://theolympiareport.com/2018/11/11/biotime-inc-btx-short-interest-up-2-0-in-october.html.

BioTime Company Profile

BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.

See Also: Do Tariffs Work?

Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.